Morepen Laboratories Ltd. Share Price

Morepen Laboratories — Why Has the Stock Nearly Doubled?

1. Q1 FY27 results were the biggest trigger Morepen reported its highest-ever quarterly revenue and earnings: Revenue: ₹570 crore, +34% YoY EBITDA: ₹87.7 crore, +207% EBITDA margin: 15.25% vs 6.65% PAT: ₹56.4 crore, +425% API business: +31% Export revenue: +111% This is the most important reason for the rerating. Profit increased much faster than revenue because of better product mix, operating leverage and improved raw-material economics. 🧬 2. ₹825 crore CDMO deal has moved into commercialisation This is arguably the biggest long-term catalyst. Morepen's previously announced ₹825 crore global CDMO mandate entered commercial execution in July 2026. The company had already completed about ₹58 crore of commercial dispatches in Q1. This changes the market perception of Morepen: Earlier: API-focused company ⬇️ Now: API + recurring CDMO manufacturing platform If the programme scales as expected, it can provide much better revenue visibility and asset utilisation. 🏭 3. Capacity expansion completed ahead of schedule On September 7, Morepen announced that the first phase of its manufacturing expansion was completed ahead of schedule. API/CDMO reactor capacity increased from: 535 KL → 614 KL The additional capacity is intended to support the commercial CDMO programme as well as existing API demand and future customer programmes. This announcement itself triggered another move in the stock, with shares rising around 7% to a fresh 52-week high. 🌎 4. Export growth has accelerated Exports increased 111% YoY in Q1, while API exports grew 42%. This is important because Morepen is increasingly targeting global pharmaceutical customers rather than depending only on the domestic API market.

See More

Morepen Labs Completes Phase-1 Capacity Expansion

has successfully completed the first phase of its manufacturing capacity expansion programme ahead of schedule. The company’s installed reactor capacity for API and CDMO operations has increased from 535 KL to 614 KL. The early completion of this phase strengthens Morepen’s ability to support growing demand in its active pharmaceutical ingredients and contract development and manufacturing organisation businesses. The expansion forms part of a multi-phase roadmap aimed at scaling capacity to meet larger global CDMO opportunities and higher-value manufacturing requirements. By enhancing reactor capacity ahead of schedule, Morepen is better positioned to execute on existing mandates and pursue additional partnerships. The development underscores the company’s focus on operational readiness and timely infrastructure upgrades to support its growth strategy in the pharmaceutical manufacturing space. *Top stocks in the API & CDMO industry:* Laurus Labs, Divi’s Laboratories, and Solara Active Pharma Sciences.

See More

Morepen Laboratories has reported a strong start to FY27

Morepen Laboratories has reported a strong start to FY27, with Q1 revenue reaching a record ₹575.31 crore, up 34% YoY, while EBITDA surged 207% to ₹87.72 crore and PAT jumped 394% to ₹56.35 crore. A major positive trigger is the ₹825 crore multi-year CDMO mandate, which has now entered full-scale commercial execution; Morepen had already completed around ₹58 crore of commercial CDMO dispatches in Q1, improving visibility for future revenue. The API business grew 31%, API exports increased 42%, while medical devices grew 19%, giving the company multiple growth engines. Morepen also completed its fourth consecutive USFDA inspection with zero Form 483 observations, strengthening its credibility with global pharmaceutical customers. The company plans to expand manufacturing capacity toward 1,200 KL by FY30, which could support larger CDMO opportunities. Overall, strong earnings growth, CDMO commercialization, export growth, API recovery and USFDA compliance are major positive triggers, while execution of the ₹825 crore mandate, capacity expansion, customer concentration and sustaining the sharp improvement in margins remain key risks. Morepen has also announced a final dividend record date of September 19, 2026

See More

Morepen Laboratories (MOREPENLAB) share price is rising

Morepen Laboratories (MOREPENLAB) share price is rising mainly because the company’s fundamentals have improved sharply: the biggest catalyst is the ₹825 crore multi-year CDMO mandate from a global pharma company, with commercial supplies already started in July 2026; this is strategically important because Morepen is moving toward the higher-margin CDMO business. In Q1 FY27, the company reported its highest-ever quarterly performance, with revenue of about ₹570 crore and PAT of ₹56.4 crore, up 394% YoY, while the CDMO program contributed to the strong improvement in profitability; API growth was also strong. Another positive is the fourth consecutive USFDA inspection with NIL 483 observations, which supports the company’s credibility in regulated export markets, while capacity is being expanded from roughly 500 KL toward 800 KL to support future manufacturing demand. The company also reported strong FY26/Q4 performance, including 22% YoY Q4 revenue growth, 69% PAT growth, 17% API growth and 31% Medical Devices growth, and proposed a 10% dividend for FY26. Therefore, the recent share-price rise appears to be driven by a combination of strong earnings growth + ₹825 crore CDMO visibility + improving margins + USFDA compliance + capacity expansion + expectations of future growth; however, after a sharp price rise, valuation and profit-booking risk should also be considered, and the delayed restructuring/hive-off of the Medical Devices

See More

Morepen Lab

Breakout retest and up, I have attached the chart so that you will understand the concept.